A recently published phase Ib study in the journal Nature Medicine reported that intrathecal administration of a Tau-targeting antisense oligonucleotides (ASO), MAPT_Rx, resulted in sustained reduction of tau protein levels with an acceptable safety profile in participants with mild Alzheimer’s disease. The article is available as an open access publication.

Professor Juha Rinne, a leading expert from our scientific team contributed in this study.

CRST is glad to be a part of this endeavor.

https://www.nature.com/articles/s41591-023-02326-3